News
RICFY
13.21
NaN%
--
Barclays Keeps Their Hold Rating on Recordati Industria Chimica e Farmaceutica SPA (0KBS)
TipRanks · 07/31 08:15
Recordati reports Q1 results
Seeking Alpha · 05/13 12:47
Recordati Q1 Net Income Rises; Confirms 2026 Financial Targets
NASDAQ · 05/13 03:48
Kepler Capital Remains a Buy on Recordati Industria Chimica e Farmaceutica SPA (0KBS)
TipRanks · 04/23 01:35
Kepler Capital Remains a Buy on Recordati Industria Chimica e Farmaceutica SPA (0KBS)
TipRanks · 03/28 04:55
Recordati Industria initiated with an Outperform at BNP Paribas
TipRanks · 03/03 09:30
Kepler Capital Sticks to Their Buy Rating for Recordati Industria Chimica e Farmaceutica SPA (0KBS)
TipRanks · 02/20 03:25
Recordati reports FY2025 results
Seeking Alpha · 02/18 18:34
Recordati Industria upgraded to Equal Weight from Underweight at Barclays
TipRanks · 02/12 11:52
Recordati Industria upgraded to Buy from Hold at Kepler Cheuvreux
TipRanks · 02/04 15:07
Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity
Seeking Alpha · 02/03 13:52
Recordati Launches Isturisa In Canada For Cushing's Disease
NASDAQ · 01/13 13:31
Weekly Report: what happened at RICFY last week (0908-0912)?
Weekly Report · 09/15/2025 10:55
Weekly Report: what happened at RICFY last week (0901-0905)?
Weekly Report · 09/08/2025 10:57
Weekly Report: what happened at RICFY last week (0825-0829)?
Weekly Report · 09/01/2025 10:53
Weekly Report: what happened at RICFY last week (0818-0822)?
Weekly Report · 08/25/2025 11:02
Weekly Report: what happened at RICFY last week (0811-0815)?
Weekly Report · 08/18/2025 10:55
More
Webull provides a variety of real-time RICFY stock news. You can receive the latest news about Recordati Industria Chimica e Farmaceutica SpA through multiple platforms. This information may help you make smarter investment decisions.
About RICFY
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based company operating in the pharmaceutical sector. The Company is engaged in the research, development, manufacture and marketing of pharmaceuticals, and its business includes two segments: Specialty & Primary Care and Rare Diseases. It promotes a range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases.